GILDGilead SciencesRunning, no new patients
Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)
Non-small Cell Lung Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 193 (final count)
- Started
- May 30, 2022
- Main results expected
- Mar 2027
- Fully finished
- Mar 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Objective Response Rate as Assessed by Independent Review Committee (IRC) per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1
Measured over: Up to 22 Months
Percentage of Participants Experiencing Dose-limiting Toxicities (DLTs) per Dose Level in the Safety Run-in Cohorts
Measured over: First dose date up to 21 days
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05186974 · record last updated 2026-09-11 · checked 2026-11-09 15:47 UTC